
Dover (DOV) Stock Forecast & Price Target
Dover (DOV) Analyst Ratings
Bulls say
Dover has demonstrated resilience with organic sales growth, though slightly below estimates, showcasing a sustained demand particularly in its biopharma and climate sustainability sectors, which contributed to an 8% growth in bookings for 3Q25. The company's strategic shift to a higher mix of Pumps & Process and Clean Energy has resulted in a robust expansion of adjusted EBITDA margins by 480 basis points from 2018 to 2024, reflecting a focus away from cyclically sensitive products. Additionally, the upward revision in total revenue growth guidance to 4%-6% at the midpoint indicates strong operational momentum, supported by favorable foreign exchange factors and strategic acquisitions.
Bears say
Dover's stock outlook appears negative due to several fundamental challenges, including a quarterly book-to-bill ratio of 0.98x that fell slightly below expectations, indicating potential revenue stagnation. Furthermore, the company's trading price-to-earnings (P/E) ratio of 17.1x for 2026 earnings expectations reflects a significant 31% discount compared to its peers, signaling concerns about its valuation and growth prospects. Additionally, the reported declines in organic sales across multiple segments, particularly the 5.1% drop in Clean Energy and 7.0% drop in Engineered Products, suggest ongoing challenges in global industrial demand and execution missteps that could impede growth.
This aggregate rating is based on analysts' research of Dover and is not a guaranteed prediction by Public.com or investment advice.
Dover (DOV) Analyst Forecast & Price Prediction
Start investing in Dover (DOV)
Order type
Buy in
Order amount
Est. shares
0 shares